Company news
Cynata Therapeutics Limited (ASX:CYP) news
Cynata Therapeutics Limited news releases on 6ix. Latest, Jun 30, 2023: Cynata announces CEO succession and Board changes
Press releases — page 2
Cynata announces CEO succession and Board changes
June 29, 2023
Cynata Completes Oversubscribed Share Purchase Plan
May 10, 2023
Share Purchase Plan Booklet & Option Prospectus
April 19, 2023
Ethics Committee Approval for Proposed aGvHD Phase 2 Trial
April 11, 2023
Capital Raising Presentation
April 5, 2023
Cynata completes $5.0m Placement and launches SPP
April 5, 2023
Cynata Adds New Sites for DFU Clinical Trial
March 16, 2023
Cynata Receives IRB Approval for aGvHD Clinical Trial
January 29, 2023
Notice of Acceptance for Cynata Australian Patent
January 9, 2023
Cynata Receives $1.65m R&D Tax Incentive Refund
December 4, 2022
Notice of Allowance for Cynata US Patent
November 10, 2022
New Kidney Transplantation Clinical Trial for Cynata & LUMC
November 1, 2022
Notice of Allowance for Australia & Canada Cymerus Patents
October 16, 2022
Successful Completion of Planned DSMB Review of DFU Trial
October 11, 2022
Grant Award to Fund Study of Cynata MSCs in Heart Disease
September 25, 2022
Pipeline Update Following Strategic Portfolio Review
August 11, 2022
Further data supports potency of Cynata MSCs
June 13, 2022
FDA Clears Cynata IND for Phase 2 Trial in GvHD
May 26, 2022
Notice of Allowance for Cynata Chinese Patent
February 27, 2022
Cynata Receives Decision to Grant a Patent in Japan
January 26, 2022
FUJIFILM Cellular Dynamics Executes Manufacturing Agreement
December 28, 2021
Cynata Commences DFU Clinical Trial
December 21, 2021
Site Initiation Visit Completed for CYP DFU Clinical Trial
November 17, 2021
Cynata Receives US$5m Fujifilm Fee
October 17, 2021
DSMB Recommends Continuation of Cynatas MEND Trial
October 7, 2021
Cynata Enters into a New Strategic Partnership with Fujifilm
September 30, 2021
Further Patents for Cynata Unique Cymerus Technology
September 15, 2021
Further Canadian Patent for Cynata
August 30, 2021
Cynata Receives Notice of Allowance from US Patent Office
August 26, 2021
Ethics Approval for Cynatas Clinical Trial in DFU
June 30, 2021
Progress Toward Clinical Trial in Diabetic Foot Ulcers
June 27, 2021
Cynata signs Licence Agreement with TekCyte
June 3, 2021
First Patient Enrolled in Cynata MEND Clinical Trial
May 24, 2021
Cynata Therapeutics : Expands MEND clinical trial in COVID-19 and Respiratory Failure
March 29, 2021
Cynata Expands trial in COVID-19 & Respiratory Failure
March 28, 2021
Cynata Therapeutics : New Preclinical Study to Investigate the High Potency of Cymerus™ MSCs
March 2, 2021
Cynata Therapeutics : Advances Planned Clinical Trial in Diabetic Foot Ulcers in MoU With TekCyte
March 1, 2021
Cynata Receives $1.39m R&D Tax Incentive Refund
February 21, 2021
Completion of Entitlement Offer and Shortfall Placement
January 17, 2021
Offer Booklet and Entitlement & Acceptance Form
December 21, 2020
Cynata Therapeutics : Secures $15m Placement Led By $10m from Healthcare Investor BioScience Managers to Expand Development Pipeline
December 11, 2020
Investor Presentation
December 10, 2020
CYP Closes $15m Institutional Placement to Expand Pipeline
December 10, 2020
Cynata Therapeutics : Phase 3 Osteoarthritis Clinical Trial Commences
November 11, 2020
Phase 3 Osteoarthritis Clinical Trial Commences
November 10, 2020
Potential Utility of Cymerus MSCs in Heart Attack Model
September 23, 2020
Cynata Therapeutics : Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study
September 8, 2020
Cymerus MSCs Effective in Preclinical Lung Disease Study
September 7, 2020
Patient Enrolment Opens in COVID-19 Clinical Trial
August 24, 2020
Cynata Appoints Dr Geoff Brooke as Chairman
August 18, 2020